STOCK TITAN

Xenetic Biosciences, Inc. - $XBIO STOCK NEWS

Welcome to our dedicated page for Xenetic Biosciences news (Ticker: $XBIO), a resource for investors and traders seeking the latest updates and insights on Xenetic Biosciences stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Xenetic Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Xenetic Biosciences's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.79%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.97%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.46%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.84%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-28.08%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.89%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.9%
Tags
conferences
Xenetic Biosciences, Inc.

NASDAQ:XBIO

XBIO Rankings

XBIO Stock Data

5.85M
1.25M
19.05%
1.1%
0.11%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
FRAMINGHAM

About XBIO

xenetic biosciences (nasdaq: xbio) is a clinical-stage biopharmaceutical company focused on discovery, research and development of next-generation biologic drugs and novel oncology therapeutics. xenetic's proprietary drug development platforms include polyxen™, which enables next generation biologic drugs by improving their half-life and other pharmacological properties. xenetic's lead investigational product candidates include fda orphan designated oncology therapeutic sodium cridanimod for the treatment of progesterone receptor negative endometrial cancer, and a polysialylated form of erythropoietin for the treatment of anemia in pre-dialysis patients with chronic kidney disease. xenetic is also working together with shire plc (formerly baxalta, baxter incorporated and baxter healthcare) to develop a novel series of polysialylated blood coagulation factors, including a next generation factor viii. this collaboration relies on xenetic's polyxen technology to conjugate polysialic acid